Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 3/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | CCKAR | P32238 | 1/20 | 0.37 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.37 |
| ▸ | PTPRB | P23467 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | CTSV | O60911 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14114876 | 0.92 | ATM (0.44) | ATMSYKAPPAKT1CTSS | |
| SCHEMBL12679280 | 0.90 | ATM (0.43) | ATMSYKAPPAKT1CTSS | |
| SCHEMBL12767695 | 0.83 | ATM (0.44) | ATMSYKAPPAKT1CTSS | |
| SCHEMBL13577915 | 0.83 | ATM (0.44) | ATMSYKAPPAKT1CTSS | |
| SCHEMBL1529414 | 0.83 | HDAC8 (0.42) | AKT1CTSSCTSLCTSBPRKCI | |
| SCHEMBL1530008 | 0.81 | HDAC8 (0.38) | CTSSCTSLCTSBPRKCIHDAC8 | |
| SCHEMBL13300074 | 0.81 | ATM (0.43) | ATMSYKAPPAKT1CTSS | |
| SCHEMBL12679237 | 0.81 | ATM (0.43) | ATMSYKAPPAKT1CTSS | |
| SCHEMBL13300010 | 0.80 | ATM (0.46) | ATMSYKAPPAKT1CTSS | |
| SCHEMBL13300017 | 0.80 | ATM (0.42) | ATMSYKAPPAKT1CTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160287561-A1 | Inhibitors of AKT Activity | NOVARTIS AG (CH) | 2016-10-06 | — | — | US | disclosed |
| US-20150152092-A1 | INHIBITORS OF Akt ACTIVITY | NOVARTIS AG (CH) | 2015-06-04 | — | — | US | disclosed |
| US-8946278-B2 | Inhibitors of AkT activity | GLAXOSMITHKLINE LLC (US) | 2015-02-03 | — | — | US | disclosed |
| US-20130231378-A1 | INHIBITORS OF AkT ACTIVITY | GLAXOSMITHKLINE LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8410158-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410158-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2013-04-02 | — | — | US | disclosed |
| US-8273782-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-8273782-B2 | Inhibitors of Akt activity | GLAXOSMITHKLINE LLC (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110071182-A1 | Inhibitors of AKT Activity | SMITHKLINE BEECHAM CORPORATION | 2011-03-24 | — | — | US | disclosed |
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION | 2010-02-18 | — | — | US | disclosed |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267759-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
| US-20130231378-A1 | INHIBITORS OF AkT ACTIVITY | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
| US-20090209607-A1 | INHIBITORS OF AKT ACTIVITY | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
| US-20160287561-A1 | Inhibitors of AKT Activity | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
| US-20110071182-A1 | Inhibitors of AKT Activity | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
| US-20150152092-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
| US-20100041726-A1 | INHIBITORS OF Akt ACTIVITY | AKT2, AKT1, AKT3 | ATM 2376/4885SYK 599/4885APP 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.